CAR T cell therapy, also known as chimeric antigen receptor T cell therapy, is a type of immunotherapy used in the treatment of certain cancers. The approach focuses on the body's immune system, particularly T cells, which play an important role in identifying and responding to abnormal cells. In this therapy, a patient's T cells are collected and genetically modified in a laboratory so they can better recognize specific markers found on cancer cells. The modified cells are then returned to the patient as part of a carefully managed treatment process.
CAR T cell therapy involves several stages that may take place over weeks. First, healthcare professionals collect T cells from the patient's blood through a process called leukapheresis. These cells are sent to a laboratory, where they are modified to produce special receptors called chimeric antigen receptors, or CARs.
The modified T cells are multiplied to create a larger number of cells. Before the CAR T cells are infused, patients may receive chemotherapy to prepare the body for the treatment. After the infusion, the modified cells can recognize particular proteins or antigens associated with targeted cancer cells.
Key parts of the CAR T cell therapy process include:
CAR T cell therapy has been used primarily for certain blood cancers, including specific types of leukemia, lymphoma, and multiple myeloma. Eligibility depends on several factors, such as the type of cancer, previous treatments, overall health, and the availability of an approved therapy for the specific condition.
One important feature of CAR T cell therapy is its personalized approach because the treatment commonly uses the patient's own T cells. These modified immune cells are designed to identify a particular target associated with cancer cells. In some patients with certain blood cancers, CAR T cell therapy may be considered when other treatment approaches have not produced the expected response or when cancer has returned.
Potential areas associated with CAR T cell therapy include:
CAR T cell therapy can also involve significant risks and requires close medical supervision. Possible side effects include cytokine release syndrome, which can cause symptoms such as fever and low blood pressure, as well as neurological effects and changes in blood cell counts. The severity of side effects can vary, and specialized healthcare teams monitor patients closely before, during, and after treatment.
Research into CAR T cell therapy continues to explore ways to improve cell design, reduce treatment related complications, and expand its potential use. Scientists are also studying how this approach may be adapted for certain solid tumors, although treating solid cancers presents different biological challenges. CAR T cell therapy remains a specialized area of cancer treatment, and decisions about its use should be based on an individual's diagnosis and guidance from qualified oncology professionals.